Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Bone Biologics (BBLG) FCF Margin (2016 - 2017)

Bone Biologics (BBLG) has disclosed FCF Margin for 2 consecutive years, with 86.65% as the latest value for Q2 2017.

  • On a quarterly basis, FCF Margin fell 47651.0% to 86.65% in Q2 2017 year-over-year; TTM through Dec 2017 was 193.68%, a 51627.0% decrease, with the full-year FY2025 number at 2136.66%, up 172777.0% from a year prior.
  • FCF Margin was 86.65% for Q2 2017 at Bone Biologics, down from 132.23% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 814.94% in Q1 2016 to a low of 86.65% in Q2 2017.